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A B S T R A C T
Background
Poorly controlled asthma often leads to preventable exacerbations that require additional medications, as well as unscheduled hospital
and clinic visits.
Long-acting beta2-agonists (LABA) are commonly given to adults with asthma whose symptoms are not well controlled by inhaled
corticosteroids (ICS). US and UK regulators have issued warnings for LABA in asthma, and now recommend they be used “for
the shortest duration of time required to achieve control of asthma symptoms and discontinued, if possible, once asthma control is
achieved”.
Objectives
To compare cessation of long-acting beta2-agonists (LABA) versus continued use of LABA/inhaled corticosteroids (LABA/ICS) for
adults whose asthma is well controlled, and to determine whether stopping LABA:
1. results in loss of asthma control or deterioration in quality of life;
2. increases the likelihood of asthma attacks or ’exacerbations’; or
3. increases or decreases the likelihood of serious adverse events of any cause.
Search methods
We searched the Cochrane Airways Group Specialised Register (CAGR), www.ClinicalTrials.gov, www.who.int/ictrp/en/, reference lists
of primary studies and existing reviews and manufacturers’ trial registries (GlaxoSmithKline (GSK) and AstraZeneca). We searched all
databases from their inception to April 2015, and we imposed no restriction on language of publication.
Selection criteria
We looked for parallel randomised controlled trials (RCTs) of at least eight weeks’ duration, in which adults whose asthma was well
controlled by any dose of ICS+LABA combination therapy were randomly assigned to (1) step-down therapy to ICS alone versus (2)
continuation of ICS and LABA.
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Data collection and analysis
Two review authors independently screened all records identified by the search strategy. We used an Excel extraction tool to manage
searches, document reasons for inclusion and exclusion and extract descriptive and numerical data from trials meeting inclusion criteria.
Prespecified primary outcomes were (1) exacerbations requiring oral steroids, (2) asthma control and (3) all-cause serious adverse events.
Main results
Six randomised, double-blind studies between 12 and 24 weeks’ long met the inclusion criteria. Five studies contributed data to the
meta-analysis, assigning 2781 people with stable asthma to the comparison of interest. The definition of stable asthma and inclusion
criteria varied across studies, and Global Initiative for Asthma (GINA) criteria were not used. Risk of bias across studies was generally
low, and most evidence was rated as moderate quality.
Stopping LABA might increase the number of people having exacerbations and requiring oral corticosteroids (odds ratio (OR) 1.74,
95% confidence interval (CI) 0.83 to 3.65; participants = 1257; studies = 4), although the confidence intervals did not exclude the
possibility that stopping LABA was beneficial; over 17 weeks, 19 people per 1000 who continued their LABA had an exacerbation,
compared with 32 per 1000 when LABA were stopped (13 more per 1000, 95% CI 3 fewer to 46 more).
People who stopped LABA had worse scores on the Asthma Control Questionnaire (mean difference (MD) 0.24, 95% CI 0.13 to 0.35;
participants = 645; studies = 3) and on measures of asthma-related quality of life (standardised mean difference (SMD) 0.36, 95% CI
0.15 to 0.57; participants = 359; studies = 2) than those who continued LABA, but the effects were not clinically relevant.
Too few events occurred for investigators to tell whether stopping LABA has a greater effect on serious adverse events compared with
continuing LABA+ICS (OR0.82, 95%CI 0.28 to 2.42; participants = 1342; studies = 5), and no study reported exacerbations requiring
an emergency department visit or hospitalisation as a separate outcome. Stopping LABA may result in fewer adverse events of any kind
compared with continuing, although the effect was not statistically significant (OR 0.83, 95% CI 0.66 to 1.05; participants = 1339;
studies = 5), and stopping LABA made people more likely to withdraw from participation in research studies (OR 1.95, 95% CI 1.47
to 2.58; participants = 1352; studies = 5).
Authors’ conclusions
This review suggests that stopping LABA in adults who have stable asthma while they are taking a combination of LABA and ICS
inhalers may increase the likelihood of asthma exacerbations that require treatment with oral corticosteroids, but this is not certain.
Stopping LABA may slightly reduce asthma control and quality of life, but evidence was insufficient to show whether this had an effect
on important outcomes such as serious adverse events and exacerbations requiring hospital admission, and longer trials are warranted.
Trialists should include patient-important outcomes such as asthma control and quality of life and should use validated measurement
tools. Definitions of exacerbations should be provided.
P L A I N L A N G U A G E S U M M A R Y
What is the evidence for stopping long-acting beta2-agonists for adults with stable asthma using combination therapy?
Stopping long-acting beta2-agonists (LABA) for adults whose asthma is stable with LABA and inhaled corticosteroid (ICS) treatment
may increase the number of asthma attacks that require treatment with extra corticosteroids, but this remains uncertain. Stopping
LABAmay also slightly reduce quality of life and asthma control. We could not tell whether stopping LABA changed serious side effects
or the likelihood of having to go to the hospital for an asthma attack.
Why is the question important?
Poorly controlled asthma often leads to attacks that require additional medications, hospital stays or treatment in the emergency
department. Long-acting beta2-agonists (LABA) are inhaled drugs that can be added to inhaled corticosteroids (ICS) to improve
symptoms and reduce asthma attacks for adults whose asthma is not well controlled by ICS alone. However, some drug authorities
have issued warnings for LABA in asthma because of safety concerns and now recommend that they be used for the shortest duration
possible, then stopped once control of asthma symptoms is achieved. We believed it was important to assess evidence provided by high-
quality studies.
How did we answer the question?
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We looked for studies at least 8 weeks’ long that compared a group of people with stable asthma who stopped taking LABA versus a
group who continued taking ICS+LABA together. We were mainly interested in determining whether stopping LABA had an effect on
asthma attacks, asthma control or side effects.
What did we find out?
We included in the data analyses five studies of people with stable asthma. We rated the overall quality of evidence as moderate for
most outcomes, meaning that additional studies are likely to change our confidence in what we found. It looked as though people who
stopped LABA might be more likely to have asthma attacks needing treatment with oral steroids, but this is uncertain. Over 17 weeks,
19 of 1000 people continuing their LABA had an attack, compared with 32 of 1000 who stopped taking LABA. This means that 13
more people in 1000 would have an attack if they stopped their LABA, but the uncertainty meant that between 3 fewer and 46 more
could be affected.
Asthma control and asthma-related quality of life were a bit worse among people who stopped taking LABA, and we could not tell
whether stopping LABA increased serious side effects or admission to the hospital.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Stopp ing LABA compared with continuing use of LABA+ICS for adults with well-controlled asthma
Patient or population: adults with asthma well controlled on LABA and ICS
Settings: outpatient
Intervention: LABA stopped
Comparison: LABA continued
Both groups were taking the same dose of ICS
Time point: calculated as the weighted mean duration of studies contributing to each analysis
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
LABA continued LABA stopped
Exacerbation: systemic
corticosteroids
17 weeks
19 per 1000 32 per 1000
(16 to 65)
OR 1.74
(0.83 to 3.65)
1257
(4 RCTs)
⊕⊕⊕©
Moderatea
Asthma control: ACQ
17 weeks
Mean ACQ score in the
control group was 0.68b
Mean score of people
who stopped LABA was
0.24 points worse (0.13
higher to 0.35 higher)
- 645
(3 RCTs)
⊕⊕⊕©
Moderatec
MCID = 0.5, so differ-
ence is not clinically sig-
nificant
Serious adverse events
17 weeks
13 per 1000 11 per 1000
(4 to 31)
OR 0.82
(0.28 to 2.42)
1342
(5 RCTs)
⊕⊕⊕©
Moderate
Asthma-related quality
of life
12 weeks
Mean asthma-
related quality of life in the
control group was 1.18
Mean score of people
who stopped LABA was
0.36 standard deviations
worse (0.15 worse to 0.
57 worse)
- 359
(2 RCTs)
⊕⊕⊕©
Moderatec,
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Exacerbation: hospital
17 weeks
0 per 1000 0 per 1000
(0 to 0)
Not estimable 1342
(5 RCTs)
⊕⊕©©
Low
No one in either group
was hospitalised for an
asthma exacerbation
Adverse events (all)
17 weeks
521 per 1000 474 per 1000
(417 to 533)
OR 0.83
(0.66 to 1.05)
1339
(5 RCTs)
⊕⊕⊕©
Moderate
Withdrawal (all)
17 weeks
159 per 1000 269 per 1000
(217 to 327)
OR 1.95
(1.47 to 2.58)
1352
(5 RCTs)
⊕⊕⊕©
Moderate
*The basis for the assumed risk (e.g.median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio; LABA: Long-acting beta2-agonists; ICS: Inhaled corticosteroids; ACQ: Asthma Control Questionnaire; AQLQ: Asthma Quality of Life Questionnaire.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aConfidence intervals include both significant harm and possible benefit of stopping LABA.
bConfidence intervals include significant benefit and harm of either treatment strategy, and 16 events were reported across all studies.
cQuality of life and asthma control are important patient-centred outcomes and were not reported by at least 3 studies (-1 publication
bias).
dDifficult to judge imprecision because the data were analysed with SMD (Reddel used the Marks AQLQ, and Berger used the Juniper,
which are coded in opposite directions on different scales). The Juniper has an MCID of 0.5, and the MD between groups in this study
was 0.37 (no downgrade).
eNo events were observed, so it was impossible to discern a difference between groups. This may be due to the length of the trials and
the severity of illness of the population (-2 imprecision).
f Confidence intervals include significant benefit of stopping LABA and do not exclude benefit of continuing LABA.
gWe planned to look at total withdrawal as it is not affected by the possible bias of assigning reasons for dropouts, but for this reason
we were unable to make assumptions about why participants were more likely to withdraw from the trial if they stopped their LABA.
hWeighted mean of control group scores in Godard 2008 and Koenig 2008 (Berger 2010 not included in calculation, as researchers
reported data as change from baseline).
iControl group endpoint score on the Marks AQLQ in Reddel 2010. Berger 2010, the only other study in the analysis, reported change
from baseline on the Juniper scale.
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B A C K G R O U N D
Description of the condition
Asthma is a long-term condition that affects the airways and is as-
sociatedwith varying degrees of cough, wheeze, shortness of breath
and chest tightness.Despite advances inmanagement, asthma con-
tinues to pose a significant economic burden, costing theNational
Health Service a billion pounds each year and causing more than a
million lost working days (BTS 2011). Costs to the health service
include direct drug and treatment costs, but a significant burden
comes from poorly controlled asthma leading to preventable exac-
erbations that require hospital stay or treatment in the emergency
department (BTS 2011).
Asthma prevalence is thought to have stabilised after increases
between 1960 and 2000. Changes varied geographically and have
been linked to various factors, including air pollution, tobacco
legislation, diet and prevalence of other atopic diseases (Anderson
2005). Current estimates of UK asthma prevalence are around 8%
for adults and 9% for children, translating to 5.4 million people
currently receiving treatment (AsthmaUK). It is estimated that the
worldwide prevalence of asthma is 250 million, with most of the
burden of disease reported in low- and middle-income countries
(Global Asthma Report 2014).
The approach to asthma management is stepwise, to gain symp-
tomcontrol and reduce future risks of exacerbationwithminimum
effective doses of medication. Therapy at step 1 consists of an as-
required short-acting beta2-agonist (SABA) for symptom control
(GINA 2014). Although some people with asthma can manage
their symptoms with as-required medications (e.g. salbutamol),
around two-thirds require regular treatment with inhaled corti-
costeroids alone or in combination with other longer-acting bron-
chodilator medications (Hoare 2003). Several national guidelines
are available for the treatment of patients with asthma in commu-
nity and emergency settings, and these recommend broadly similar
treatment steps aimed at achieving and maintaining daily symp-
tom control while preventing exacerbations (BTS/SIGN 2012;
GINA 2014; NAEPP 2007).
Description of the intervention
Inhaled corticosteroids (ICS) are the primary recommended pre-
vention therapy for people with persistent asthma who do not gain
sufficient control by using as-needed reliever medications (step 2)
(BTS/SIGN 2012; GINA 2014). Regular use of ICS has been
shown to improve lung function while reducing the need for re-
liever medications (Adams 2008; Adams 2009).
National treatment guidelines recommend long-acting beta2-ago-
nists (LABA) as the preferred add-on therapy to ICS when a per-
son does not achieve asthma control with ICS and short-acting re-
liever medication (BTS/SIGN 2012; GINA 2014). Combination
therapy with LABA+ICS can be given at low dose at step 3, and at
medium or high dose at step 4. Evidence from randomised trials
has shown that adding LABA to ICS improves lung function and
symptoms, and reduces the frequency of exacerbations, in adults
whose asthma is not well controlled by ICS alone (Ducharme
2008), and that this approach is preferable to increasing ICS dose
(Ducharme 2010).
However, despite demonstrated benefits of LABA add-on ther-
apy in adults, large studies and meta-analyses have shown a link
between beta2-agonist use and increased asthma morbidity and
mortality (Cates 2014; Nelson 2006; Salpeter 2006), leading in
2005 to a US Food and Drug Administration (FDA) black box
warning - the most severe warning applied to prescription medica-
tion to highlight increased risk of serious adverse events (Aaronson
2006). FDA analyses of clinical trials showed “increased risk of se-
vere worsening of asthma symptoms, leading to hospitalisation in
both children and adults and death in some patients with asthma”
(FDA 2010). As a result, the FDA has mandated that drug com-
panies must conduct clinical trials to assess the safety of LABA
used in asthma, with trials expected to yield results by 2017. It has
not been established whether either of the two most widely used
LABA - salmeterol or formoterol - is safer than the other in adult
asthma (Cates 2014).
Although investigators have shown that the detrimental effects of
regular LABA are reduced when used in combination with ICS
(Cates 2014; Ernst 2006), particularly when the two drugs are de-
livered in a combination inhaler (FDA 2010), a Cochrane review
was not able to conclude whether risk of adverse events remains
higher with the combination than with ICS alone (Ducharme
2008). In line with the stepwise approach to asthma treatment
(BTS/SIGN 2012; GINA 2014), manufacturers’ labels are re-
quired to state that LABA should be used only “for the shortest
duration of time required to achieve control of asthma symptoms
and discontinued, if possible, once asthma control is achieved”.
How the intervention might work
Inhaled corticosteroids reduce mucus buildup and exacerbations
by reducing inflammation in the airways (Barnes 1993), and can
be taken once (fluticasone furoate) or twice daily (e.g. beclometha-
sone, budesonide, fluticasone propionate). LABA can also be taken
once (vilanterol) or twice daily (formoterol, salmeterol), and act
as a bronchodilator by relaxing bronchial wall smooth muscle
(Nelson 1995).
Much debate has surrounded possible causal links between LABA
and increased mortality and morbidity (Cates 2012; Tattersfield
2006). Theories of LABA-related death and adverse events include
direct toxicity of the drugs themselves (in particular, their cardiac
effects (e.g. Brown 1983)), reduced response over time causing
gradual worsening of disease (Lipworth 1997) and delay in receiv-
ing medical help caused by masking of underlying inflammation
(the delay hypothesis (e.g. Bijl-Hofland 2001)). It has been sug-
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gested that the delay hypothesis is linked to a reduction in compli-
ance with appropriate ICS treatment (Johnston 2009), although
this is largely a historical issue that has arisen since the introduction
of combination inhalers. Confounding by severity, in the sense
that people with more severe disease are likely to be taking LABA,
has now been dismissed, as it cannot explain the overall increase
in mortality reported in the 1960s and 1970s, and in the light of
evidence from large case-control studies (e.g. Crane 1989).
A UK confidential inquiry into asthma mortality in 2012-2013
identified 195 deaths attributable to asthma (National Review of
Asthma Deaths (NRAD) 2014). Of these, a significant propor-
tion of patients showed poor compliance with medication regi-
mens (48%) or were overusing short-acting beta2-agonists (39%)
- potential confounding factors that could influence outcomes in
this review.
Why it is important to do this review
Despite established evidence of safety issues associated with use of
LABA in uncontrolled asthma, only limited data are available to
support or guide discontinuation once asthma control is achieved.
It is unclear whether potential risks of stopping LABA for patients
who have achieved asthma control (i.e. increased likelihood of
exacerbations and reduced quality of life) outweigh potential risks
of continuing LABA therapy.
The risk-benefit ratiomay be different in children and adolescents,
as “the risks of hospitalisation and poor outcomes are of particu-
lar concern for children” (FDA 2010), and particular issues with
compliance may be seen among the younger population. For this
reason, all child and adolescent studies will be synthesised in a
separate review.
O B J E C T I V E S
To compare cessation of long-acting beta2-agonists (LABA) versus
continued use of LABA/inhaled corticosteroids (LABA/ICS) for
adults whose asthma is well controlled, and to determine whether
stopping LABA:
1. results in loss of asthma control or deterioration in quality of
life;
2. increases the likelihood of asthma attacks or ’exacerbations’; or
3. increases or decreases the likelihood of serious adverse events of
any cause.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included parallel randomised controlled trials (RCTs) of at
least 8 weeks’ duration. We included studies reported as full-text
articles, those published as abstracts only and unpublished data.
We did not include cross-over trials, as they are not suitable for
assessing long-term outcomes.
Types of participants
We included studies of adults age 18 or older whose asthma is
currently well controlled with any dose of maintenance long-act-
ing beta2-agonists (LABA) and inhaled corticosteroids (ICS). Par-
ticipants’ asthma control was classified according to prespecified
criteria (e.g. a score lower than 1.5 on the Asthma Control Ques-
tionnaire (ACQ)), or the criteria for control described in GINA
2014 guidelines (i.e. daytime symptoms and need for rescue in-
haler twice or less often per week, with no nocturnal symptoms or
limitations in daily activities).
If researchers included both adults and children and did not pro-
vide data for adults alone, we included studies if mean age was
over 18 in both groups of participants. When studies were found
that included only a subset of relevant participants, we included
them only if study authors were able to provide disaggregated data
for participants who fit the inclusion criteria. We excluded studies
that included participants with other chronic respiratory co-mor-
bidities (e.g. chronic obstructive pulmonary disease).
Types of interventions
We included studies in which adults whose asthma was well con-
trolled by any dose of ICS+LABA combination therapy were ran-
domly assigned to:
1. step-down therapy to ICS alone (continued at the same
dose received before randomisation); or
2. continued use of ICS and LABA (any preparation at the
same dose received before randomisation).
We included any LABA (formoterol, salmeterol, vilanterol) and
any dose of ICS (budesonide, mometasone, fluticasone propi-
onate, fluticasone furoate) used to treat asthma delivered in a com-
bination inhaler or in separate inhalers. We allowed studies in
which researchers gave a different ICS to participants in the inter-
vention group, provided it was given at the same beclomethasone
dipropionate (BDP) equivalent dose as the ICS received before
LABA was stopped, as this may reflect what happens in practice
(e.g. replacing salmeterol/fluticasone with beclomethasone).
One possible treatment strategy for asthma at step 4 is to reduce
the dose of LABA and ICS concurrently, once asthma control
has been achieved (rather than stopping LABA); however, we did
not include in the review studies addressing the effects of this
intervention, as this is a separate clinical question.
We included trials that allowed short-acting reliever medications,
provided they were not given as part of the randomly assigned
treatment.
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Types of outcome measures
Primary outcomes
1. Exacerbation requiring systemic corticosteroids.
2. Asthma control* (measured on a validated scale, e.g.
Asthma Control Questionnaire (ACQ)).
3. Serious adverse events (all cause).
Primary outcomes were chosen to represent an important measure
of resource use, a patient-important outcome and safety.
Secondary outcomes
1. Quality of life* (measured on a validated scale, e.g. Asthma
Quality of Life Questionnaire).
2. Exacerbations requiring hospitalisation or emergency
department visit (participants with at least one).
3. Adverse events (all cause).
4. Withdrawals.
Reporting in the trial one or more of the outcomes listed here was
not an inclusion criterion for the review.
*If more than one scale measuring the same construct is reported
within a study, or if different scales are used across studies, we will
analyse results using standardised mean differences.
Search methods for identification of studies
Electronic searches
We identified trials from the Cochrane Airways Group Specialised
Register (CAGR), which is maintained by the Trials Search Co-
ordinator for the Group. The Register contains trial reports iden-
tified through systematic searches of bibliographic databases in-
cluding theCochrane Central Register of Controlled Trials (CEN-
TRAL), MEDLINE, EMBASE, the Cumulative Index to Nurs-
ing and AlliedHealth Literature (CINAHL), the Allied and Com-
plementary Medicine Database (AMED) and PsycINFO, and by
handsearching of respiratory journals and meeting abstracts (see
Appendix 1 for further details). We searched all records in the
CAGR using the search strategy presented in Appendix 2.
We also conducted a search of
ClinicalTrials.gov (www.ClinicalTrials.gov) and theWorld Health
Organization (WHO) trials portal (www.who.int/ictrp/en/). We
searched all databases from their inception up to April 2015, and
we imposed no restriction on language of publication.
Searching other resources
We checked reference lists of all primary studies and review arti-
cles to look for additional references. We searched relevant manu-
facturers’ websites (GlaxoSmithKline (GSK) and AstraZeneca) for
trial information, and we contacted field experts to request infor-
mation about unpublished or ongoing studies.
On 3 March 2015, we searched for errata or retractions
from included studies published in full text on PubMed
(www.ncbi.nlm.nih.gov/pubmed).
Data collection and analysis
Selection of studies
Two review authors (KK and SA) independently screened titles
and abstracts for inclusion of all potential studies identified as a
result of the search, and coded them as ’retrieve’ (eligible or poten-
tially eligible/unclear) or ’do not retrieve’. We retrieved the full-
text study reports or publications, and two review authors (KK
and SA) independently screened the full-text articles to identify
studies for inclusion. We identified and recorded reasons for ex-
clusion of ineligible studies, resolving disagreements through dis-
cussion or, if required, by consultation with a third person. We
identified and excluded duplicates and collatedmultiple reports of
the same study, so that each study, rather than each report, is the
unit of interest in the review. We recorded the selection process
in sufficient detail to complete a PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) flow diagram
and a Characteristics of excluded studies table.
Data extraction and management
We used a Microsoft Excel data collection form, which has been
piloted on at least one study in the review, to document study
characteristics and outcome data. Both review authors (KK and
SA) extracted the following study characteristics from included
studies.
1. Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and locations, study
setting, withdrawals, date of study.
2. Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria, exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, time points reported.
5. Notes: funding for trial, notable conflicts of interest of trial
authors.
One review author (KK) independently extracted outcome data
from included studies. We noted in the Characteristics of included
studies table if outcome data were not reported in a useable way.
We resolved disagreements by reaching consensus or by involving
a third person. One review author (KK) transferred data into the
Review Manager (Review Manager (RevMan)) file. We double-
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checked that data were entered correctly by comparing data pre-
sented in the systematic review versus those provided in the study
reports. A second review author (SA) spot-checked study charac-
teristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (KK and SA) independently assessed risk of
bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved disagreements by discussion or through involvement
of a third person.We assessed risk of bias according to the following
domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as high, low or unclear,
and provided a quote from the study report, together with a jus-
tification for our judgement, in the ’Risk of bias’ table. We sum-
marised ’Risk of bias’ judgements across different studies for each
of the domains listed. We considered blinding separately for dif-
ferent key outcomes when necessary (e.g. for unblinded outcome
assessment, risk of bias will be greater for quality of life ratings than
for number of exacerbations). When information on risk of bias
was related to unpublished data or correspondence with a study
author, we noted this in the ’Risk of bias’ table.
When uncertainties were due to insufficient reporting, we con-
tacted the study author or the sponsor for additional information.
When considering treatment effects, we took into account risk of
bias for studies that contributed to this outcome.
Assesment of bias in conducting the systematic
review
We conducted the review according to the published protocol and
reported deviations from it in the Differences between protocol
and review section.
Measures of treatment effect
We analysed dichotomous data as odds ratios, and continuous
data as mean differences or standardised mean differences. We
entered data presented as a scale with a consistent direction of
effect. We narratively described skewed data reported as medians
and interquartile ranges.
We undertook meta-analyses only when this was meaningful (i.e.
when treatments, participants and the underlying clinical question
were similar enough for pooling to make sense).
When multiple trial arms were reported in a single trial, we in-
cluded only the relevant arms. When two comparisons (e.g. drug
A vs placebo and drug B vs placebo) were combined in the same
meta-analysis, we halved the control group to avoid double-count-
ing.
When changes from baseline and endpoint scores were available
for continuous data, we used changes from baseline unless most
studies reported endpoint scores.When a study reported outcomes
at multiple time points, we used the end-of-study measurement.
When both an analysis using only participants who completed
the trial and an analysis imputing data for participants who were
randomly assigned but did not provide endpoint data (e.g. last
observation carried forward) were available, we used the latter.
Unit of analysis issues
For dichotomous outcomes, we used participants rather than
events as the unit of analysis (i.e. number of adults admitted to the
hospital rather than number of admissions per adult). However,
if exacerbations were reported as rate ratios, we analysed them on
this basis.
Dealing with missing data
We contacted investigators or study sponsors to verify key study
characteristics and to obtain missing numerical outcome data
when possible (e.g. when a study was identified as an abstract
only). When this was not possible, and missing data were thought
to introduce serious bias, we explored the impact of including
such studies in the overall assessment of results by performing a
sensitivity analysis.
Assessment of heterogeneity
We used the I² statistic to measure heterogeneity among the trials
in each analysis. If we identified substantial heterogeneity, we re-
ported this and explored possible causes by performing prespeci-
fied subgroup analyses.
Assessment of reporting biases
As we did not have more than 10 trials for pooling, we did not cre-
ate and examine a funnel plot to explore possible small study and
publication biases. We considered the impact of unpublished trials
in the GRADE (Grades of Recommendation, Assessment, Devel-
opment and Evaluation) ratings for each outcome (GRADEpro;
Higgins 2011).
Data synthesis
We used a random-effects model for all analyses, as we expected
variation in effects due to differences in study populations and
methods. We performed sensitivity analyses using a fixed-effect
model.
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’Summary of findings’ table
We created a ’Summary of findings’ table to present data for the
seven prespecified outcomes. We presented the pooled analysis in
each case, and noted in the comments column significant differ-
ences between subgroups. We used the five GRADE considera-
tions (study limitations, consistency of effect, imprecision, indi-
rectness and publication bias) to assess the quality of a body of
evidence as it related to studies that contributed data to the meta-
analyses for prespecified outcomes. We used methods and recom-
mendations as described in Section 8.5 and Chapter 12 of the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011) by using GRADEpro software. We justified all decisions to
downgrade or upgrade the quality of studies by using footnotes,
and we made comments when necessary to aid the reader’s under-
standing of the review.
Subgroup analysis and investigation of heterogeneity
We planned the following subgroup analyses for primary out-
comes, using the formal test for subgroup differences provided in
Review Manager (version 5.3) (Review Manager (RevMan)).
1. Mean steroid dose (according to GINA 2014, defined as
low, medium and high cutoffs).
2. Type of inhaler used in the comparison group (LABA/ICS
combination inhaler vs separate inhalers).
3. Type of LABA being stopped (formoterol, salmeterol).
Mean steroid dose of the population in each study may reflect
differences in disease severity and may have effects on outcomes
after LABA therapy is stopped. We used the boundaries for low,
medium and high as described in GINA 2014 for ex-actuator
doses.
Participants using combination inhalers may be less likely to ex-
perience potential adverse effects of LABA treatment, as this re-
moves the risk associated with taking the LABA inhaler without
ICS. Combination inhalers may also be associated with generally
better compliance with treatment.
Differences in stopping different types of LABA may be due to
variations in pharmacological properties and duration of action.
Sensitivity analysis
We planned to carry out sensitivity analyses for the primary anal-
yses, excluding the following.
1. Studies at high risk of bias for blinding.
2. Unpublished data (i.e. no peer-reviewed full paper
available).
R E S U L T S
Description of studies
We included in the Characteristics of included studies section
detailed descriptions of studies fulfilling the criteria specified in the
protocol. We compiled excluded studies for which full texts were
viewed, along with reasons for exclusion, in the Characteristics of
excluded studies section.
Results of the search
Database searching retrieved 400 references, and our additional
searches of industry databases and relevant reference lists yielded
635 records. We removed three duplicates, leaving 1032 unique
references. Of these, we excluded 990 after sifting titles and ab-
stracts and assessed full texts of the remaining 42 studies. Twenty-
six of these did not meet the inclusion criteria (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
Six studies (16 citations) met the inclusion criteria, but one re-
ported no outcomes that could be included in our meta-analysis
(Slankard 2011). Descriptions from here on will relate to the five
studies that contributed data to themeta-analysis. Those five stud-
ies randomly assigned 2781 people with a diagnosis of asthma to
the comparisons of interest in this review. GSK SAS40037 con-
tributed the largest sample size to the analyses, with 824 people
randomly assigned across four intervention groups. Reddel 2010
included the smallest number of people, with 82 participants ran-
domly assigned to the two arms relevant to this review.
Design and duration
All five studies in the quantitative analysis were multi-centre, ran-
domised, parallel-group controlled trials, taking place at between
three and 124 centres. One study, Slankard 2011, was included
only in the qualitative analysis and was not a multi-centre trial. All
studies were double-blind. Berger 2010 andReddel 2010 had a du-
ration of 12 weeks. The duration of treatment in GSK SAS40037,
Koenig 2008 and Slankard 2011 was 16 weeks, and Godard 2008
lasted for 24 weeks but reported its primary outcome at 12 weeks.
All studies had a run-in period, which varied between studies
from two weeks to eight weeks, when participants received usual
ICS+LABA therapy with rescue SABA.
Participant inclusion and exclusion criteria
We provided detailed explanations of inclusion and exclusion cri-
teria in Characteristics of included studies. All trials included out-
patients at least 15 years of age; mean participant age was above
18 years, leading us to treat them as adult studies. All participants
had a diagnosis of stable or well-controlled asthma characterised
at study entry, but criteria varied. For inclusion based on stable
asthma, Berger 2010 based definitions of mild tomoderate asthma
on ICS use, Godard 2008 assessedwhether current asthma therapy
controlled asthma, GSK SAS40037 required a forced expiratory
volume of 1 second (FEV1) of 40% to 85% of their predicted
normal value, Koenig 2008 required an FEV1 between 40% and
80% of their predicted value and Reddel 2010 required that par-
ticipants had not had an exacerbation in the preceding four weeks.
None of the trials used the Global Initiative for Asthma (GINA)
definition for mild to moderate asthma or the Asthma Control
Questionnaire (ACQ) as part of the inclusion criteria. All trials
recruited participants taking regular ICS and LABA therapy with
an as-needed SABA rescue inhaler. Three studies excluded par-
ticipants with a smoking history ≥ 10 pack-years (Godard 2008;
Reddel 2010; Slankard 2011). Four studies excluded people who
had recently taken systemic corticosteroids (Berger 2010, Godard
2008 and Koenig 2008 within one month, Reddel 2010 within
three months).
Baseline characteristics of participants
We extracted baseline characteristics of participants from each trial
and presented them in the Characteristics of included studies sec-
tion, along witha summary in Table 1.
Participants’ ages across trials had a similar mean value in each
trial, ranging from 40 to 49 years. All trials recruited more women
than men (between 34.8% male in Slankard 2011 and 49% male
in Reddel 2010). Trials that provided demographic information
described a predominantly Caucasian sample population (ranging
from 82.6% to 88% white). Participants’ mean percentage pre-
dicted FEV1 was reported in three trials, ranging between 83%
and 91% at randomisation (Berger 2010; Godard 2008; Reddel
2010).
Characteristics of the interventions
In all studies, a combination ICS+LABA inhaler was administered
before step-down to LABA, and in four of five studies included
in the analysis, the LABA was salmeterol: salmeterol/fluticasone
50/250 mcg twice daily in Godard 2008 and Reddel 2010, and
salmeterol/fluticasone 50/100 mcg twice daily in GSK SAS40037
and Koenig 2008. In Berger 2010, the combination therapy was
formoterol/budesonide 9/160 mcg twice daily (Table 1). No stud-
ies used a different ICS in the comparison group than in the inter-
vention group. All studies used albuterol as the relievermedication
in acute exacerbations.
The design of Reddel 2010 meant that only data reported at week
12 were relevant to this review, as ICS were downtitrated between
week 12 and the 52 week endpoint.
Outcomes and analysis structure
Asthma exacerbations were not uniformly defined, but we were
able to confirmdata for the primary outcomewith the author team
of another review, who had obtained unpublished information
directly from the study sponsors (Brozek 2012). We incorporated
additional unpublished data from this review for some studies in
the ACQ and quality of life analyses with permission from the
review authors. We removed these unpublished data in a planned
sensitivity analysis.
Several measures of asthma control were used in these studies,
and not all were validated. We analysed the ACQ and narratively
summarised data from other non-validated measures, including
percentage of symptom- and rescue-free days and the number of
people meeting GINA definitions for totally controlled and well-
controlled asthma.
We subgrouped results according to the ICS+LABA combination
used in the comparison group (i.e. fluticasone/salmeterol or budes-
onide/formoterol), but it was not possible to perform planned
subgroup analyses for ICS dose or inhaler type because the studies
were similar in these respects.
Excluded studies
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We excluded 26 records after viewing full texts, in most cases
because the study was not designed to test the effects of stopping
LABA versus continuing it. We excluded two studies because they
used a cross-over design, which was prespecified as exclusionary in
our protocol, and two studies likely to meet the inclusion criteria
have not yet been completed (NCT01437995; NCT02094937).
We outlined details of reasons for exclusion of studies in the
Characteristics of excluded studies section.
Risk of bias in included studies
We outlined details of risk of bias for each included study and rea-
soning behind ratings in Characteristics of included studies, and a
summary of risk of bias judgements by study and domain (selec-
tion bias, performance bias, detection bias, attrition bias, report-
ing bias, other bias) can be found in Figure 2.Most ratings in most
domains for included studies were low risk, with the exception of
attrition bias and other bias.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
All of the included studies were described as randomised, but very
little published information was available on the methods used in
any of the included studies.One study described random sequence
generation in sufficient detail to warrant a low risk rating (Reddel
2010), and the other studies were given low risk ratings on the basis
of prior contact with study sponsors. Slankard 2011 was published
as an abstract and provided inadequate information regarding the
randomisation procedure, so bias was rated as unclear.
Blinding
Across studies, we found no evidence of risk of bias related to
blinding of participants or observers. All studies were described
as double-blind, and study authors described measures such as
matched inhalers to hide group allocation from participants and
personnel; we therefore assumed that those measuring outcomes
were also blinded.
Incomplete outcome data
Risk of bias due to high or unbalanced dropout was mixed across
studies. We rated one study (GSK SAS40037) as high risk because,
although all randomly assigned participants were included in the
analysis, dropout was high in both groups and was higher in the
group for which LABA was stopped, which may have led to un-
derestimation of the effects. We rated two studies as unclear be-
cause, although the dropout rate was low overall, it was somewhat
unbalanced and was much higher in the ICS group (14%) than
in the LABA+ICS group (4%) (Reddel 2010), or the number of
withdrawals was not reported (Koenig 2008); we rated two studies
as low risk.
Selective reporting
All named outcomes were reported in the published reports or
were made available by study authors or sponsors via a previous
review team (Brozek 2012), and we rated all included studies as
low risk. We rated Slankard 2011 as high risk because the data
could not be included in the meta-analysis, and several outcomes
were not reported at all. Only a conference abstract was available;
therefore this was used for qualitative analysis only.
Other potential sources of bias
During the course of the Koenig 2008 study, recruitment of par-
ticipants was placed on hold pending analysis of data from the
Salmeterol Multicenter Asthma Resarch Trial (SMART) and was
subsequently terminated, with approximately 161 participants per
treatment group (target was 206 per group). It is unclear whether
potential sources of bias threatened the validity of the findings,
or the size and direction of the treatment effect. We identified no
other sources of bias in the remaining studies.
Effects of interventions
See: Summary of findings for the main comparison Stopping
LABA compared with continuing use of LABA+ICS for adults
with well-controlled asthma
Primary outcomes
Exacerbation requiring systemic corticosteroids
Nineteen people per 1000 who continued their LABA had an
exacerbation, compared with 32 per 1000 for whom LABA was
stopped (13 more per 1000, 95% CI 3 fewer to 46 more). Confi-
dence intervals did not exclude the possibility that stopping LABA
was better (OR 1.74, 95% CI 0.83 to 3.65; participants = 1257;
studies = 4; I2 = 0%; moderate quality; Analysis 1.1), so we down-
graded the quality of the evidence for imprecision. A sensitivity
analysis using only the published data yielded a slightly larger
point estimate with similar imprecision (OR 1.89, 95% CI 0.85
to 4.22).
Asthma control
People who stopped their LABA had worse scores on the Asthma
Control Questionnaire (ACQ) than those who continued (MD
0.24, 95% CI 0.13 to 0.35; participants = 645; studies = 3; I2 =
0%; Analysis 1.2), but the effect was around half the size of the es-
tablishedminimal clinically important difference (MCID) for this
scale, which is 0.5 units (Juniper 1999). We rated the evidence as
of moderate quality, having downgraded this for possible publica-
tion bias because three studies did not report what we considered
to be a very important outcome. Data for two of the studies were
not available in published reports but were included with permis-
sion from Brozek 2012, who acquired additional data from the
study sponsors for inclusion in their systematic review. Without
this unpublished data, the effect favoured continuing LABA to a
lesser extent and was very imprecise (MD 0.12, 95% CI -0.24 to
0.48).
We chose not to meta-analyse several other measures related to
’control’ that were reported in these studies; some were inconsis-
tently reported, and others were not measured on validated scales.
Four studies reporting diary card data showed loss of control mea-
sured as symptom-free days, and three saw a reduction in rescue-
free days and night-time awakenings. These outcomes were con-
sidered to provide low-quality evidence because variation in the
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magnitude and direction of effects was evident across studies, and
because metrics of asthma control were considered indirect or in-
complete.
Godard 2008 usedGINA-defined criteria for ’well-controlled’ and
’totally controlled’ asthma, and found that 47% of those for whom
LABA were stopped were considered ’totally controlled’ and 77%
’well controlled’ after 24 weeks, compared with 73% and 85% of
those who continued combination therapy.
Reddel 2010 measured a ’Total Asthma Score’ based on a compos-
ite score of asthma symptoms, rescue use and peak flow over the
preceding four weeks (Reddel 2010 supplement) and found no
differences between groups (4.74 (SD 2.21) in those who stopped
LABA, 4.54 (SD 2.21) in those who continued LABA).
Serious adverse events (all cause)
All studies reported serious adverse events but only 16 events were
observed, so it was not clear if stopping LABA was safer than
continuing LABA (OR 0.82, 95% CI 0.28 to 2.42; participants
= 1342; studies = 5; I2 = 0%; Analysis 1.3). We downgraded the
evidence for imprecision and rated it as moderate quality because
confidence intervals included significant benefit and harm for both
treatment strategies. None of the data were unpublished, so there
was no need to perform a sensitivity analysis.
Secondary outcomes
Asthma-related quality of life
Quality of life declined in those who stopped taking their LABA
compared with those who continued, but this was measured on
two different scales with different properties, so it is unclear
whether the difference was clinically significant (SMD 0.36, 95%
CI 0.15 to 0.57; participants = 359; studies = 2; I2 = 0%). Data
for Berger 2010 were not reported sufficiently in the published
reports for inclusion in the meta-analysis, but complete data were
included with permission from Brozek 2012, who acquired addi-
tional data from the study sponsors. Berger 2010 also reported a
responder analysis for the Asthma Quality of Life Questionnaire
(AQLQ) (6.6% vs 14%) that was not statistically significant but
supported the findings of the main AQLQ analysis. Evidence was
rated of moderate quality because the outcome was available in
only two of the included studies, so we deemed that publication
bias was possible.
Exacerbations requiring hospitalisation or emergency
department visit
None of the included studies reported this outcome separately, so
no data were available for analysis. We downgraded the evidence
twice for imprecision and rated the quality as low, but the lack of
events might have reflected the length of studies conducted or the
severity of participants recruited.
Adverse events (all cause)
Fewer people who stopped their LABA had adverse events, al-
though the upper confidence interval did not exclude the possi-
bility that stopping LABA was harmful (OR 0.83, 95% CI 0.66
to 1.05; participants = 1339; studies = 5; I2 = 4%; Analysis 1.6).
We downgraded the evidence for this imprecision and rated the
quality as moderate.
Withdrawals
More people who stopped taking their LABA dropped out before
completion of the studies (OR 1.95, 95% CI 1.47 to 2.58; partic-
ipants = 1352; studies = 5; I2 = 6%; Analysis 1.7). We planned to
look at total withdrawals, as they are not affected by the possible
bias of assigning reasons for dropouts, but for this reason, we were
unable to make assumptions about why participants were more
likely to withdraw from the trial if they stopped their LABA than
if they continued LABA. We downgraded the evidence for indi-
rectness for this reason and rated the quality as moderate.
Subgroup analyses
Mean ICS dose
All studies reporting exacerbations requiring systemic steroids used
ICS doses classified as low in GINA 2014, so it was not possible
to perform the subgroup analysis.
Inhaler type
All studies reporting exacerbations requiring oral steroids used
combination inhalers, so it was not possible to perform the sub-
group analysis.
Type of LABA
We subgrouped included studies by the LABA that was deliv-
ered in the comparison group. Three studies reporting exacerba-
tions requiring systemic steroids used salmeterol and one used for-
moterol, and the test for subgroup differences was not significant
(I2 = 0%; Analysis 2.1). Confidence intervals for each subgroup
effect were very wide because of the small quantity of available
data, so it is difficult to know whether a difference was present that
was not detected. For asthma control measured on the ACQ, the
effect favouring continuing LABA was larger in the study using
formoterol than in the two using salmeterol, but the test for sub-
group differences was not significant (I2 = 28%, P = 0.24; Analysis
2.2), and this determination was based on a very small number of
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studies. For serious adverse events, the effect was more in favour
of stopping LABA in the formoterol study than in the four that
used salmeterol, but confidence intervals were very wide and over-
lapping; the test for subgroup differences was not significant (I2 =
0%; Analysis 2.3).
Sensitivity analysis
Studies at high risk of bias for blinding
We rated no studies as having high risk of bias for either of the
blinding domains, so a sensitivity analysis on this basis was not
necessary.
Unpublished data
We removed from the primary outcomes in sensitivity analyses
additional unpublished data included with permission from the
authors of Brozek 2012. . We reported these results under each of
the primary outcomes.
D I S C U S S I O N
Summary of main results
Six randomised, double-blind studies between 12 and 24 weeks
long met the inclusion criteria. The five studies contributing data
assigned 2781 people with stable asthma to the comparison of
interest (stepping down from LABA+ICS to ICS alone) or to the
control group (continuation of LABA+ICS), although the defini-
tion of stable asthma and the inclusion criteria varied across stud-
ies.
In the primary analysis, evidence from four studies indicated that
stopping LABAmight increase the number of people having exac-
erbations requiring systemic corticosteroids, but the effect was not
statistically significant, as the confidence intervals did not exclude
the possibility that stopping LABA was beneficial; over 17 weeks,
19 people per 1000 who continued their LABA had an exacerba-
tion, compared with 32 per 1000 for whom LABA was stopped
(13 more per 1000, 95% CI 3 fewer to 46 more).
Moderate-quality evidence suggests that stopping LABA was as-
sociated with loss of asthma control as measured by the ACQ and
with worse asthma-related quality of life than for those who con-
tinued LABA, but the effects were not clinically significant. Other
unvalidated measures of control, such as symptom-free days and
use of reliever medication, were presented in a narrative synthesis
and showed variable results. No included study reported exacerba-
tions requiring an emergency department visit or hospitalisation
as a separate outcome.
Serious adverse events were too rare in these studies to show
whether stopping LABA was better or worse than continuing
LABA; this may be a reflection of the severity of illness among
participants and of study duration. Stopping LABA may result in
fewer adverse events of any kind comparedwith continuing LABA,
but this effect was not statistically significant, and stopping LABA
made people more likely to withdraw from research studies.
Overall completeness and applicability of
evidence
We were unable to perform the subgroup analyses that we had set
out in the protocol. As all of the studies reporting exacerbations
requiring systemic steroids used ICS doses classified as low in
GINA 2014, and as all used combination inhalers, it was not
possible to perform subgroup analyses for mean ICS dose or for
inhaler type.
Although all included studies had stable asthma as part of their in-
clusion criteria, no standardised internationally recognised severity
parameter grading system such as GINA 2014 (or other severity
scoring systems) was used. This would have reduced potential clin-
ical heterogeneity between studies andwould have increased appli-
cability for a clinical audience. Treatment protocols for the inter-
vention varied between studies in terms of medication, dosage and
frequency, and inconsistencies in how LABA was stepped down
were observed.
Some outcomes with great clinical importance, such as quality of
life, were sparsely reported, with only two studies providing data
on these. In addition, we could not comment on long-term effects
of stopping LABA, as all included studies were of relatively short
duration - between 12 and 24 weeks - possibly not sufficient for
long-term effects to become apparent. Serious adverse events were
reported at the end of each study period, and if further events
occurred beyond this time, they could not be recorded, which may
impact the completeness of evidence. A recent overview of LABA
safety in asthma highlighted three ongoing long-term trials that
will be best placed to assess the safety implications of prolonged
combination therapy (Cates 2014).
Baseline demographics indicated a Caucasian bias among partici-
pants. A more diverse study population would increase generalis-
ability of the results.
Quality of the evidence
Review authors assessed the quality of the outcome data by us-
ing GRADEpro software and recommendations provided by The
Cochrane Collaboration; we summarised results of this analysis
in Summary of findings for the main comparison. We assessed all
outcomes except exacerbations requiring hospital admission or an
emergency department visit as of moderate quality, but we down-
graded evidence quality for a variety of reasons. Heterogeneity
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across individual outcomes was not statistically significant, as re-
flected by low I2 values.
We downgraded both asthma control and asthma-related quality
of life on the basis that although they are important patient-centred
outcomes, they were not reported by investigators in at least three
of the studies.
We downgraded the evidence for exacerbations requiring systemic
corticosteroids and for exacerbations requiring hospital or emer-
gency department treatment because of imprecision. In the case of
exacerbations requiring systemic corticosteroids, confidence inter-
vals show both significant harm and possible benefit of stopping
LABA. For exacerbations requiring hospital or emergency depart-
ment treatment, no events were observed. This may reflect both
duration of the trials and asthma severity in the studied popula-
tions. Similarly, evidence for both serious adverse events and all
adverse events was downgraded because of imprecision.
Indirectness is more challenging to assess. The recruited popula-
tion of participants with stable asthmamay not have been themost
appropriate group on whom to assess outcomes such as exacer-
bations requiring systemic corticosteroids and hospital admission,
given the short duration of the studies, leading to few events and
imprecision. However, all outcomes are directly clinically relevant
and are not surrogate markers.
To resolve uncertainties related to risk of bias and missing data,
we made an effort to contact all study authors. We received an
acknowledgement of contact fromReddel 2010, Koenig 2008 and
Slankard 2011. Reddel 2010 provided additional data, and we
received no response from GSK SAS40037.
Potential biases in the review process
Standard Cochrane methods were used to create this review pro-
cess. Two independent review authors extracted study character-
istics and numerical data and resolved discrepancies through dis-
cussion and, if necessary, consultation with a third independent
review author. Two independent review authors also made risk of
bias decisions. Review authors reported no conflicts of interest.
Two independent review authors performed extensive literature
searches and subsequent screening of published data and confer-
ence abstracts. Studies were not limited by language of publica-
tion. Given that a thorough search strategy was used, it is unlikely
that any available published studies were missed by the study se-
lection process. Review authors also attempted to contact all study
authors to obtain additional information about outcomes and to
clarify study methods to ensure accurate risk of bias decisions. We
received detailed replies and additional data from one study au-
thor; others did not receive the request or were unable to provide
the information requested.
Agreements and disagreements with other
studies or reviews
We identified an existing systematic review conducted by Brozek
2012 to assess evidence supporting discontinuation of LABA ther-
apy in adults and older children with stable asthma controlled
by a combination of ICS and LABA. We included supplemental
data from this review in this Cochrane review with their permis-
sion. Their inclusion criteria differed from ours, as they included
children (lower limit age cutoff was four years) and restricted
LABA type to salmeterol or formoterol. Their search strategy
yielded the same five studies identified by our independent search
strategy (Berger 2010; Godard 2008; GSK SAS40037; Koenig
2008; Reddel 2010). We identified these and an additional study
(Slankard 2011), although this latter study could not be included
in our quantitative analysis, as we had insufficient information
beyond the abstract. The conclusion from Brozek 2012 was that
no statistically significant results were reported for any outcomes
that would demonstrate benefit derived from LABA step-down
compared with continued use of LABA and ICS.
Brozek 2012 assessed additional outcomes, such as morning peak
flow and prebronchodilator peak flow rates, and included unpub-
lished quality of life data. Disagreements regarding evidence qual-
ity ratings were noted between this review and Brozek 2012, with
the latter downgrading most outcomes for indirectness because re-
view authors noted that studies did not always make clear whether
participants were well controlled on long-term combination ther-
apy, or whether they had been given combination therapy during
a run-in as part of the study. They also noted the issue regarding
the short duration of studies with particular relevance to the out-
comes for which events were rare (e.g. hospital admissions, serious
adverse events).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review suggests that stopping LABA in adults who have stable
asthmawhile taking a combination of LABA and ICS inhalersmay
increase the likelihood of asthma exacerbations requiring treat-
ment with systemic corticosteroids, but this was not certain. Stop-
ping LABAmay slightly reduce asthma control and quality of life,
but evidence was insufficient to permit judgement on the possi-
bility of an effect on other important outcomes such as serious
adverse events and exacerbations requiring hospital admission.
Implications for research
Given the clinical importance of this question and its relevance
to international guidelines, it is perhaps surprising that only six
studies met our inclusion criteria, leading to limited conclusions.
Given the relative infrequency of exacerbations, especially severe
exacerbations, longer trials are warranted. Trialists should include
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patient-important outcomes such as asthma control and quality
of life and should use validated measurement tools. Definitions
of exacerbations should be provided, Our inability to perform
subgroup analysis according to baseline ICS dose suggests that
further trials examining the effects of stepping down for those
requiring higher doses of ICS are warranted.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Berger 2010
Methods Design: randomised, double-blind, parallel-group, double-dummy, placebo- and active-
controlled multi-centre trial
Enrolment commenced in April 2003, and the study was completed in June 2004. The
trial included 116 centres in the USA. Duration of treatment was 12 weeks
Participants Population: 752 eligible participants with stable asthma after a run-in period were ran-
domly assigned in a 1:1:1:1:1 ratio at each site to receive the following: The comparison
of budesonide/formoterol 80/4.5 mcg × 2 inhalations twice daily and budesonide 160
mcg × 2 inhalations once daily was relevant to this review, but participants were also
randomly assigned to budesonide/formoterol 160/4.5 mcg × 2 inhalations once daily,
budesonide/formoterol 80/4.5 mcg × 2 inhalations once daily and placebo pMDI × 2
inhalations twice daily
Baseline characteristics: control group: 37.7% male, mean age 38, 85.7% Caucasian,
predicted FEV1 86.4 (9.1). Intervention group: 31.7% male, mean age 38.6, 81.4%
Caucasian, predicted FEV1 85.7 (8.8)
Inclusion criteria: patients ≥16 years of age (no upper age limit recorded) with ATS
defined asthma for 6+ months, mild to moderate based on ICS use and pulmonary
function, use of low to medium doses of ICS during the month before screening and a
pre-BD FEV1 between 60% and 90% predicted normal
Exclusion criteria: participants with a significant medical condition that might put
them at risk, influence their ability to participate in the study or influence study results.
Participantswith anymalignancy (other thanbasal cell carcinoma)within the past 5 years,
a clinically significant laboratory test abnormality or a clinically significant abnormal
electrocardiogram (ECG) also were excluded. Patients requiring systemic corticosteroids
in the previous month were excluded at screening
Interventions Run-in: During the 4- to 5-week run-in period, eligible participants discontinued their
current asthma therapy and received single-blind treatment with budesonide/formoterol
80/4.5 mcg twice daily and as needed rescue albuterol
Intervention (LABA stopped): 2 of the 5 treatment arms were relevant and are analysed
in our review. The intervention group was the group in which LABA was stepped-down,
budesonide 160 mcg × 2 inhalations was given once daily for 12 weeks, and rescue
albuterol was taken if required
Control (LABA+ICS): budesonide/formoterol 80/4.5 mcg × 2 inhalations twice daily
for 12 weeks. Rescue albuterol was taken if required
Outcomes Primary: morning and evening peak expiratory flow (PEF) and morning and evening
pre-dose FEV1
Secondary: spirometry (FEV1) at clinic visits at 2, 6 and 12 weeks, daytime and night-
time symptom scores, night-time awakenings due to asthma, rescue medication use,
patient withdrawals due to worsening asthma control (according to predefined criteria)
, Asthma Quality of Life Questionnaire, standardised version (AQLQ(S)) results, diary
card data, adverse events, vital signs, cortisol levels and physical examination findings
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Notes Funding: AstraZeneca
Study number: AstraZeneca study code: D5896C00726, SD-039-0726; clinical trial
registration number: NCT00652392
Symptom-free day: a day with no daytime or night-time asthma symptoms and no
awakenings due to asthma
Rescue-free day: a calendar day with no daytime or night-time rescue medication use
Clinical exacerbation: an exacerbation requiring emergency treatment, hospitalisation
or use of an asthma medication not allowed by the protocol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Not sufficiently described in published re-
ports, but previous contact with study
sponsors confirmed standard practice with
computerised codes
Allocation concealment (selection bias) Low risk Not sufficiently described in published re-
ports, but previous contact with study
sponsors confirmed concealed automated
allocation system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy. Medica-
tions given by identical delivery devices to
maintain study blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, double-dummy. Medica-
tions given by identical delivery devices to
maintain study blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout < 20% in both groups, 99% in-
cluded with imputation in the efficacy and
safety analyses
Selective reporting (reporting bias) Low risk Full AQLQ results were not reported but
had been previously been acquired by an-
other review team, who shared the data
Other bias Low risk None identified
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Godard 2008
Methods Design: randomised, double-blind, parallel-group multi-centre trial
Study period was 13 May 2002 to 6 November 2003. Trial included 124 centres in
France. Duration of treatment was 24 weeks
Participants Population: 475 eligible participants with well-controlled asthma after a run-in period
of 8 weeks were randomly assigned to receive fluticasone propionate/salmeterol 250/50
mcg twice daily, fluticasone propionate/salmeterol 100/50 mcg twice daily or fluticasone
propionate 250 mcg twice daily
Baseline characteristics:
control group: 51.9%male, mean age 46.5, 85.7%Caucasian, predicted FEV1 87.8 (18.
2). Intervention group: 48.7% male, mean age 42, 81.4% Caucasian, predicted FEV1
90.8 (17.2)
Inclusion criteria: male and female participants≥ 18 years oldwith documented history
of asthma (≥ 6 months), whose asthma was controlled with current treatment (1000 mg
of inhaled beclomethasone dipropionate or equivalent and a long-acting beta2-agonist)
at a stable dose for at least 4 weeks
Exclusion criteria: smoking history ≥ 10 pack-years, respiratory tract infection dur-
ing the last 4 weeks before the initial clinic visit, acute asthma exacerbation requiring
emergency room treatment or hospitalisation within 4 weeks before the initial clinic
visit and/or use of oral/parenteral corticosteroids during the past 4 weeks (12 weeks for
depot corticosteroids) or any change in their asthma maintenance treatment in the pre-
vious 4 weeks. Changes in asthma medication (excluding study rescue medication) or
insufficient asthma control according to daily record card or ACQ and/or investigator’s
judgement regarding the suitability of a reduction in maintenance treatment
Interventions Run-in: 8-Week run-in period during which all participants received open-label sal-
meterol/fluticasone propionate combination 50/250 mcg. All previous asthma control
medications were discontinued with the exception of short-acting bronchodilator rescue
medication used by the patient previously and antihistamines. At the end of the run-
in period, asthma control was assessed and participants were randomly assigned if they
fulfilled the weekly criteria for ’well-controlled’ asthma (as defined in Gaining Optimal
Asthma Control (GOAL) study criteria) during the last 2 weeks of the run-in period
Intervention (LABA stopped): 2 of the 3 treatment arms were relevant; these are anal-
ysed in our review. The intervention group was the group in which LABA was stepped-
down: fluticasone propionate 250 mcg × twice daily for 24 weeks. Rescue short-acting
bronchodilators were taken if required
Control (LABA+ICS): salmeterol/fluticasone propionate 50/250 mcg twice daily for 24
weeks. Rescue short-acting bronchodilators were taken if required
Outcomes Primary: The primary endpoint was mean morning peak expiratory flow (PEF) over the
first 12 weeks of treatment
Secondary: morning PEF over the last 12 weeks of the treatment period, evening PEF,
daily symptoms, short-acting bronchodilator use as rescue medication, exacerbations,
forced expiratory volume in 1 second (FEV1) and asthma control using the GOAL
definitions of total and well-control
Notes Funding: GlaxoSmithKline (GSK)
Study number: GSK study code SAM40088 (SFCF4026)
Definitions: moderate exacerbation: worsening of asthma leading to a prescription for
short use of oral corticosteroids. Severe exacerbation: worsening of asthma leading to
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hospitalisation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Not sufficiently described in published re-
ports, but previous contact with study
sponsors confirmed standard practice with
computerised codes
Allocation concealment (selection bias) Low risk Not sufficiently described in published re-
ports, but previous contact with study
sponsors confirmed concealed automated
allocation system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No specific details but described as double-
blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No specific details but described as double-
blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropout < 20% in both groups, somewhat
lower in the LABA/ICS group. All ran-
domly assigned participants were included
in the ITT population
Selective reporting (reporting bias) Low risk All named outcomes were reported in the
published report or were made available by
study author or sponsor via a previous re-
view team
Other bias Low risk None identified
GSK SAS40037
Methods Design: randomised, double-blind, double-dummy, parallel-group multi-centre trial
Study period was 29 October 2001 to 29 May 2003. Trial included 99 centres in the
United States, of which 87 randomly assigned participants. Duration of treatment was
16 weeks
Participants Population: 824 eligible participants with well-controlled asthma after a run-in period
of 8 weeks were randomly assigned to receive fluticasone propionate/salmeterol 250/50
mcg twice daily, fluticasone propionate/salmeterol 100/50 mcg twice daily or fluticasone
propionate 250 mcg twice daily
Baseline characteristics: control group: 58% male, mean age 41, 83% Caucasian. In-
tervention group: 67% male, mean age 42, 81.4% Caucasian
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GSK SAS40037 (Continued)
Inclusion criteria: male and female participants, 15 years of age or older, with a diagnosis
of asthma, as defined by the ATS, for at least 6 months before the first visit. Each
participantmust have been treatedwith an allowed inhaled corticosteroid at a fixeddosing
regimen (within an allowed total daily dose) for at least 4 weeks before the screening visit.
All participants were required to have FEV1 of 40% to 85% of their predicted normal
value and ≥ 12% reversibility within 30 minutes following 2 to 4 puffs of albuterol
inhaler at the screening visit
Documentation of historical reversibility within 24 months was allowed
Exclusion criteria: Participants were not allowed to participate if they had been diag-
nosed with life-threatening asthma, were hospitalised for asthma within the previous
6 months, had a concurrent respiratory disease or had intermittent or seasonal asthma
alone. Participants also could not have had a respiratory tract infection or used antibiotics
for treatment of a suspected or diagnosed respiratory tract infection within 14 days of
visit 1
Interventions Run-in: 2-Week run-in phase during which participants continued their current inhaled
corticosteroid therapy, followed by an open-label treatment period during which those
who did not achieve asthma control replaced this with fluticasone propionate/salmeterol
100/50 mcg twice daily. Those who achieved control during the open-label period were
randomly assigned to 16 weeks of blinded treatment with fluticasone propionate/salme-
terol 100/50 mcg twice daily, fluticasone propionate 100 mcg twice daily, salmeterol 50
mcg twice daily or montelukast 10 mg 4 times a day. Albuterol was allowed as a rescue
short-acting bronchodilator for each group
Intervention (LABA stopped): 2 of the 3 treatment arms were relevant to our protocol;
these are analysed in this review. The intervention group was the group in which LABA
was stepped-down: fluticasone propionate 100 mcg × twice daily for 16 weeks
Control (LABA+ICS): fluticasone propionate/salmeterol 100/50 mcg twice daily for 16
weeks
Outcomes Primary: mean change from baseline at endpoint in morning PEF
Secondary: mean change from baseline at endpoint in morning predose FEV1, percent-
age of symptom-free days, percentage of rescue-free days and participant-rated satisfac-
tion with treatment
Notes Funding: GlaxoSmithKline (GSK)
Study number: GSK study code SAS40037
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Not sufficiently described in published re-
ports, but previous contact with study
sponsors confirmed standard practice with
computerised codes
Allocation concealment (selection bias) Low risk Not sufficiently described in published re-
ports, but previous contact with study
sponsors confirmed concealed automated
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allocation system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No specific details but described as double-
blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No specific details but described as double-
blind
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout unbalanced and high in both
groups; higher in ICS group (34%) than
in LABA+ICS group (24%). All randomly
assigned participants were included in the
ITT analysis
Selective reporting (reporting bias) Low risk All named outcomes were reported in the
published report or were made available by
study author or sponsor via a previous re-
view team
Other bias Low risk None identified
Koenig 2008
Methods Design: randomised, double-blind, double-dummy, parallel-group multi-centre trial
Study period was 29 October 2001 to 28 May 2003. Trial included 97 centres in the
United States, of which 85 randomly assigned participants. Duration of treatment was
16 weeks
Participants Population: 647 participants with stable asthma while taking fluticasone propionate/
salmeterol 100/50 mcg twice daily were randomly assigned to receive fluticasone propi-
onate 100 mcg twice daily, salmeterol 50 mcg twice daily or montelukast 10 mg once
daily
Baseline characteristics: control group: 39% male, mean age 40.4, 88% Caucasian.
Intervention group: 43% male, mean age 42, 87% Caucasian
Inclusion criteria: male or female participants ≥ 15 years of age with a diagnosis of
asthma using the ATS definition. Eligible participants had to demonstrate prebron-
chodilator FEV1 between 40% and 80% of predicted normal. Participants also had to
demonstrate at visit 1 or provide historical evidence of reversible airway disease charac-
terised by an increase in FEV1 > 12% within 30 minutes after inhalation of albuterol, or
1 standard dose of nebulised albuterol. Eligible participants used 1 of the following ICS
at a fixed daily dosing regimen for at least 4 weeks before screening: beclomethasone 160
to 240 mcg/d; budesonide 200 to 400 mcg/d; flunisolide 1000 mcg/d; fluticasone pro-
pionate MDI 176 to 220 mcg/d; fluticasone propionate dpi 200 mcg/d; triamcinolone
acetonide 600 to 1000 mcg/d
Exclusion criteria: life-threatening asthma, asthma instability, concurrent respiratory
disease, intermittent and seasonal asthma or exercise-induced bronchospasm alone or
any other concurrent condition/disease that would put safety of participants at risk.
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Concurrent use of medications that could affect the course of asthma or interact with
study medications was prohibited. Systemic corticosteroid use was prohibited within 4
weeks of screening
Interventions Run-in: 2-Week run-in phase during which participants continued their current inhaled
corticosteroid therapy, followed by an open-label treatment period only for those who did
not achieve asthma control. Inhaled corticosteroids were replaced with fluticasone pro-
pionate/salmeterol 100/50 mcg (Advair Diskus, GSK) twice daily. Those who achieved
control during the open-label period were then randomly assigned to 16 weeks of blinded
treatment with fluticasone propionate/salmeterol 100/50 mcg twice daily, fluticasone
propionate 100 mcg twice daily, salmeterol 50 mcg twice daily or montelukast 10 mg 4
times a day. Albuterol was allowed as a rescue short-acting bronchodilator in all groups
Intervention (LABA stopped): 2 of the 4 treatment arms were relevant to our protocol;
these are analysed in this review. The intervention group was the group in which LABA
was stepped-down: fluticasone propionate 100 mcg twice daily for 16 weeks
Control (LABA+ICS): fluticasone propionate/salmeterol 100/50 mcg twice daily for 16
weeks
Outcomes Primary: mean change from baseline at endpoint in morning PEF
Secondary: mean change from baseline at endpoint in morning predose FEV1, percent-
age of symptom-free days, percentage of rescue-free days, asthma symptom scores, night-
time awakenings, participant-related satisfaction on treatment questionnaire
Notes Funding: GlaxoSmithKline (GSK)
Study number: GSK study code SAS40036
Definitions: rescue-free day: day without use of rescue albuterol
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Not sufficiently described in published re-
ports, but previous contact with study
sponsors confirmed standard practice with
computerised codes
Allocation concealment (selection bias) Low risk Not sufficiently described in published re-
ports, but previous contact with study
sponsors confirmed concealed automated
allocation system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind, double-dummy study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, double-dummy study
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of participants who dropped out
during the study was not given. Study au-
thors stated that the ITT population was
used, which consisted of all participants
who were randomly assigned to treatment
Selective reporting (reporting bias) Low risk All named outcomes were reported in the
published report or were made available by
study author or sponsor via a previous re-
view team
Other bias Unclear risk During the course of the study, participant
recruitment was placed on hold pending
analysis of data from the Salmeterol Multi-
center Asthma Research Trial and was sub-
sequently terminated, with approximately
161 participants per treatment group (tar-
get was 206 per group)
Reddel 2010
Methods Design: block-randomised, double-blind, parallel-group, multi-centre study conducted
at 3 centres in Australia
Study period was from 28 March 2002 to 17 February 2006
Participants Population: 82 participants with asthma were block randomly assigned to receive sal-
meterol/fluticasone 50/500 mcg twice daily or fluticasone 500 mcg twice daily alone
Inclusion criteria: male or female, 18 to 80 years of age with a clinical diagnosis of
asthma (according to ATS criteria) for 6 months who had been taking salmeterol and
fluticasone for at least 4 weeks at a daily dose of 50/500 mcg twice a day by Diskus or by
pressurised metered dose inhaler. Showed evidence of adequate unsupervised spirometric
technique, had completed > 60% of run-in diary card sessions and had not experienced
an exacerbation within the previous 4 weeks
Exclusion criteria: current smoking or > 10 pack-year smoking history, significant
chronic respiratory disease or evidence of extrathoracic airway obstruction, pregnancy
or lactation, use of oral/parenteral corticosteroids or hospitalisation for asthma in the
previous 3 months or respiratory tract infection within the previous 4 weeks. Those
experiencing a severe exacerbation were withdrawn but could be re-enrolled 3 months
after cessation of systemic corticosteroids. Treatment with asthma medications, other
than study medications and corticosteroids for exacerbations, was not permitted
Interventions Run-in: During the 4-week run-in period, participants received open-label salmeterol
and fluticasone propionate 50/500 mcg twice daily via Diskus
Intervention (LABA stopped): fluticasone 500 mcg twice a day for 12 weeks
Control (LABA+ICS): salmeterol and fluticasone propionate 50/500 mcg twice daily
via Diskus plus rescue beta2-agonist for symptom relief
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Outcomes Primary: mean daily fluticasone propionate dose including ICS for exacerbations
Secondary: minimum effective ICS dose, dose reduction failure (exacerbation),
FEV1, FVC, PD20 methacholine, ACQ, AQLQ, optimal asthma control, % sputum
eosinophils and neutrophils, blood eosinophils, exacerbations, exhaled nitric oxide,
asthma-free days, average rescue medication use per day, average morning and evening
FEV1 and PEF, adverse events
Notes Funding: GlaxoSmithKline
Study number: clinical trial registration number ACTRN12605000465651 (Australian
and New Zealand Clinical Trial Registry). GSK Trial register: SAM40031
Definitions: moderate exacerbation: increase in rescue beta agonist use by 2 occasions
and/or fall in PEF by ≥ 2 standard deviations from baseline mean on 2 of 3 consecutive
days
Severe exacerbation: increase in rescue beta agonist use by≥ 2occasions in a day compared
with baseline, and fall in PEF ≥ 3 standard deviations from baseline mean on 2 of 3
consecutive days
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation (week 0) was conducted
by GSK Australia by computer-generated
schedule and was stratified by duration of
SFC treatment (6 months and > 6 months)
, with a permuted block design (block size
of 4 randomisation numbers)
Allocation concealment (selection bias) Low risk Not sufficiently described in published re-
ports, but previous contact with study
sponsors confirmed concealed automated
allocation system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Identified by dose level and by a unique
randomly assigned pack number to main-
tain blinding and concealment of randomi-
sation allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Identified by dose level and by a unique
randomly assigned pack number to main-
tain blinding and concealment of randomi-
sation allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout low overall but somewhat unbal-
anced; much higher in ICS group (14%)
than in LABA+ICS group (4%). 96% of
participants were included in the analyses
presented
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Selective reporting (reporting bias) Low risk All named outcomes were reported in the
published report or were made available by
study author or study sponsor via a previous
review team
Other bias Low risk None identified
Slankard 2011
Methods Design: randomised, double-blind, parallel-group trial
Start date of study: June 2007. Final data collection date: November 2010. Clinical trials
portal lists this study as ’ongoing’ but not recruiting participants
Duration of treatment: 16 weeks
Participants Population: 69 participants who had been genotyped were randomly assigned to con-
tinue on the same dose of LABA-ICS or to step down to ICS alone
Baseline characteristics: individual group characteristics unknown
Inclusion criteria: men or women ≥ 18 years of age, history of moderate or severe and
persistent asthma, currently being treated with a long-acting beta2-agonist and inhaled
corticosteroid, FEV1 ≥ 70% at randomisation visit. Women of childbearing potential
must be taking an effective form of contraception. Literate in English
Exclusion criteria: active smoking or > 10 pack-year history of smoking, history of
intubation for asthma within the past 10 years, pregnancy or breast feeding, major co-
morbidity including severe cardiac disease, uncontrolled hypertension, poorly controlled
diabetes, malignancy within the past 5 years (except non-melanoma skin lesions) and
other pulmonary disease
Interventions Run-in: 6-Week run-in phase during which participants continued their current inhaled
ICS-LABA therapy
Intervention: LABA stopped for 16 weeks
Control: LABA+ICS for 16 weeks
Outcomes Primary: absolute change from baseline at endpoint in morning PEF
Secondary: absolute and percentage change in rescue inhaler use
Notes Funding: unknown
Study number: ClinicalTrials.gov Identifier: NCT00521222
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; no additional de-
tails
Allocation concealment (selection bias) Unclear risk No details
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk No specific details but described as double-
blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No specific details but described as double-
blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details of dropout or imputation
Selective reporting (reporting bias) High risk No data could be included in the meta-
analysis, and several outcomes were not re-
ported at all. Only a conference abstract
was available
Other bias Low risk None identified
ACQ: asthma control questionnaire; ATS: American Thoracic Society; AQLQ: asthma quality of life questionnaire; FEV1: forced
expiratory volume in one second; FVC: forced expiatory volume; ICS: inhaled corticosteroids; ITT: intention to treat; LABA: long-
acting beta2-agonist; PD20: histamine provocation dose causing a 20% drop in FEV1; PEF: peak expiratory flow.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aalbers 2005 LABA was not stopped - wrong comparison
Bumbacea 2010 This paper was not about stepping down LABA - wrong comparison
Cowie 2007 LABA was not stepped down - wrong comparison
FitzGerald 2003 LABA was not stepped down - wrong comparison
Fowler 2002 ICS dose was higher in the step-down group - wrong comparison
GSK ADA109315 Not a LABA step-down study - wrong comparison. This was an analysis of healthcare utilisation and costs of
stepping down LABA
GSK SMS30046 Cross-over study - wrong study design
Harrison 1997 LABA was not stepped down - wrong comparison
Ind 2004 LABA was not stepped down - wrong comparison
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Liu 2007 Not a LABA step-down study - wrong comparison. Assessing usefulness of monitoring airway hyperresponsive-
ness to guide dose adjustment
Nathan 2009 LABA was not stepped down - wrong comparison
NCT01565031 No clear step-down strategy for LABA - wrong comparison
Obase 2013 ICS dose was stepped down - wrong comparison
Paggiaro 2011 LABA was not stepped down - wrong comparison
Papi 2012 LABA was not stepped down - wrong comparison
Self 1998 ICS dose was stepped down - wrong comparison
Shamsul 2007 2 step-down groups - wrong comparison
Zangrilli 2009 LABA was not stepped down - wrong comparison
Characteristics of ongoing studies [ordered by study ID]
NCT01437995
Trial name or title Long-acting beta agonist step down study (LASST)
Methods 6-Week, multi-centre, blinded, randomised, double-masked, parallel-group comparative effectiveness study
of approaches to stepping down therapy for patients with well-controlled asthma treated with combination
ICS and LABA
Participants Inclusion criteria: men and women 12 to 80 years of age with well-controlled asthma taking moderate dose
of ICS/LABA based on an Asthma Control Test (ACT) score ≥ 20, absence of unscheduled visits or use of
rescue prednisone for 4 weeks before enrolment and a prebronchodilator FEV1 ≥ 70% predicted
Exclusion criteria: long-term oral steroid therapy, hospitalisation or urgent care visit within 4 weeks of
screening visit, lung disease other than asthma including COPD, bronchiectasis, sarcoidosis or other lung
disease. < 10 pack-years of tobacco use and abstinence, postbronchodilator FEV1 < 70% predicted, near-
fatal asthma (intubation or ICU admission for asthma) within 2 years of enrolment, high risk of near-fatal
or fatal asthma, history of known premature birth less than 33 weeks or any significant level of respiratory
care including prolonged oxygen administration or mechanical ventilation during the neonatal period, un-
stable cardiac disease (decompensated CHF, unstable angina, recent MI, atrial fibrillation, supraventricular
or ventricular tachycardia, congenital heart disease or severe uncontrolled hypertension), other major chronic
illnesses, drug allergies, pregnancy, lactation
Interventions Stepping down from fluticasone/salmeterol diskus 250/50 mcg bd to fluticasone diskus 250 mcg bd without
salmeterol
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Outcomes Rate of treatment failure assessed by decline in peak flow or FEV1, increased need for beta-agonists, require-
ment for non-scheduled medical care for asthma symptoms or prednisone taper
Pulmonary function measures: (1) morning peak expiratory flow rate (from participants’ daily diary cards)
and (2) pre-BD FEV1 and bronchodilator response
Rate of episodes of poor asthma control (EPAC) defined by unscheduled medical care, hospitalisation, use of
oral corticosteroids and/or increased use of rescue medications and/or decrease of 30% or more in morning
PEFR
Starting date March 2012
Contact information Joy Saams, Registered Nurse
Notes Estimated enrolment: 450. Estimated study completion date: June 2015
NCT02094937
Trial name or title 201135: a randomised, double-blind, multi-centre, parallel-group study to compare the efficacy and safety
of fluticasone furoate (FF) 100 mcg once daily with fluticasone propionate (FP) 250 mcg twice daily (BD)
and FP 100 mcg BD in well-controlled asthmatic participants stepped down from maintenance therapy with
RELVAR inhaler (FF/VI) 100/25 mcg once daily in Japanese participants
Methods Randomised, multi-centre, double-blind, placebo-controlled, parallel-group study
Participants Inclusion criteria: men and women ≥ 18 years of age with a diagnosis of asthma as defined by the National
Institutes of Health at least 1 year before screening visit. Asthma must be ’stable’ as judged by the investigator
with no change in asthma medication for at least 8 weeks before screening and an ACT score ≥ 20. Best
prebronchodilator FEV1 ≥ 80% of predicted normal value at screening visit. Using the middle-dose ICS/
LABA, equivalent to twice-daily combination of fluticasone propionate and salmeterol 250 mcg for at least
12 weeks before registration visit. In addition, the prescription of the middle-dose ICS/LABA should not be
changed at least 8 weeks before
Exclusion criteria: history of life-threatening asthma, recent respiratory tract infection, exacerbation of
asthma requiring oral corticosteroids in the previous 12 weeks, other respiratory disease, other significant co-
morbidities, smoker or history of smoking ≥ 10 pack-years
Interventions 4 experimental arms. Arms of interest to this review are fluticasone furoate/vilanterol 100/25 mcg and the
comparison arm of those receiving fluticasone furoate 100 mcg bd alone
Outcomes Time to withdrawal due to poorly controlled asthma during weeks 8 to 20. Proportion of participants with
well-controlled asthma at the end of week 20, mean change from baseline in clinic visit trough FEV1 at the
end of period 2, mean change from baseline in the percentage of symptom-free 24-hour periods during week
20, mean change from baseline in percentage of rescue-free 24-hour periods during period 2, mean change
from baseline in Asthma Control Test (ACT) score during weeks 8 to 20, proportion of participants with
ACT score ≥ 20 at the end of week 20
Starting date March 2014
Contact information US GSK Clinical Trials Call Center
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Notes Estimated study completion date: June 2015
Sponsored by GlaxoSmithKline
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D A T A A N D A N A L Y S E S
Comparison 1. Stopped LABA vs continued LABA+ICS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Exacerbation: systemic
corticosteroids
4 1257 Odds Ratio (M-H, Random, 95% CI) 1.74 [0.83, 3.65]
2 Asthma control: ACQ 3 645 Mean Difference (IV, Random, 95% CI) 0.24 [0.13, 0.35]
3 Serious adverse events 5 1342 Odds Ratio (M-H, Random, 95% CI) 0.82 [0.28, 2.42]
4 Asthma-related quality of life 2 359 Std. Mean Difference (IV, Random, 95% CI) 0.36 [0.15, 0.57]
5 Exacerbation: hospital admission
or emergency department visit
5 Odds Ratio (M-H, Random, 95% CI) Totals not selected
6 Adverse events (all cause) 5 1339 Odds Ratio (M-H, Random, 95% CI) 0.83 [0.66, 1.05]
7 Withdrawals (all) 5 1352 Odds Ratio (M-H, Random, 95% CI) 1.95 [1.47, 2.58]
Comparison 2. Subgroup analysis: type of LABA
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Exacerbation: requiring systemic
corticosteroids
4 1257 Odds Ratio (M-H, Random, 95% CI) 1.74 [0.83, 3.65]
1.1 Formoterol 1 296 Odds Ratio (M-H, Random, 95% CI) 2.13 [0.19, 23.71]
1.2 Salmeterol 3 961 Odds Ratio (M-H, Random, 95% CI) 1.70 [0.78, 3.72]
2 Asthma control: ACQ 3 645 Mean Difference (IV, Random, 95% CI) 0.24 [0.13, 0.35]
2.1 Formoterol 1 290 Mean Difference (IV, Random, 95% CI) 0.32 [0.15, 0.49]
2.2 Salmeterol 2 355 Mean Difference (IV, Random, 95% CI) 0.19 [0.05, 0.33]
3 Serious adverse events 5 1342 Odds Ratio (M-H, Random, 95% CI) 0.82 [0.28, 2.42]
3.1 Formoterol 1 299 Odds Ratio (M-H, Random, 95% CI) 0.35 [0.04, 3.40]
3.2 Salmeterol 4 1043 Odds Ratio (M-H, Random, 95% CI) 1.05 [0.31, 3.60]
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Analysis 1.1. Comparison 1 Stopped LABA vs continued LABA+ICS, Outcome 1 Exacerbation: systemic
corticosteroids.
Review: Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids
Comparison: 1 Stopped LABA vs continued LABA+ICS
Outcome: 1 Exacerbation: systemic corticosteroids
Study or subgroup LABA stopped LABA continued Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Berger 2010 (1) 2/144 1/152 9.5 % 2.13 [ 0.19, 23.71 ]
Godard 2008 (2) 16/154 9/154 76.3 % 1.87 [ 0.80, 4.37 ]
GSK SAS40037 (3) 1/161 1/161 7.1 % 1.00 [ 0.06, 16.13 ]
Koenig 2008 (4) 1/159 1/172 7.1 % 1.08 [ 0.07, 17.45 ]
Total (95% CI) 618 639 100.0 % 1.74 [ 0.83, 3.65 ]
Total events: 20 (LABA stopped), 12 (LABA continued)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.32, df = 3 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours stopping LABA Favours continued LABA
systemic corticosteroids)
(1) ”A clinical exacerbation was defined as an exacerbation requiring emergency treatment, hospitalization, or use of an asthma medication not allowed by the protocol”
(assumed to include
(2) Requiring oral corticosteroids
(3) ”Any use of systemic corticosteroids” (From Brozek 2012. obtained from study sponsor)
(4) Data for Koenig 2008 and SAS40037 have been incorporated with permission from Brozek et al (provided to them by the study sponsor)
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Analysis 1.2. Comparison 1 Stopped LABA vs continued LABA+ICS, Outcome 2 Asthma control: ACQ.
Review: Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids
Comparison: 1 Stopped LABA vs continued LABA+ICS
Outcome: 2 Asthma control: ACQ
Study or subgroup LABA stopped LABA continued
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Berger 2010 (1) 139 0.38 (0.811) 151 0.06 (0.632) 40.9 % 0.32 [ 0.15, 0.49 ]
Godard 2008 141 0.8 (0.6) 142 0.6 (0.7) 50.2 % 0.20 [ 0.05, 0.35 ]
Reddel 2010 (2) 35 1.13 (0.86) 37 1.01 (0.69) 8.9 % 0.12 [ -0.24, 0.48 ]
Total (95% CI) 315 330 100.0 % 0.24 [ 0.13, 0.35 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.56, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 4.41 (P = 0.000011)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours stopping LABA Favours continuing LABA
(1) Data for Berger 2010 and Reddel 2010 have been incorporated with permission from Brozek et al (provided to them by the study sponsor)
(2) Visit 4 (week 12) data before ICS were titrated
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Analysis 1.3. Comparison 1 Stopped LABA vs continued LABA+ICS, Outcome 3 Serious adverse events.
Review: Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids
Comparison: 1 Stopped LABA vs continued LABA+ICS
Outcome: 3 Serious adverse events
Study or subgroup LABA stopped LABA continued Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Berger 2010 1/145 3/154 22.7 % 0.35 [ 0.04, 3.40 ]
Godard 2008 1/154 3/154 22.7 % 0.33 [ 0.03, 3.20 ]
GSK SAS40037 2/161 1/161 20.2 % 2.01 [ 0.18, 22.42 ]
Koenig 2008 0/159 0/172 Not estimable
Reddel 2010 (1) 3/41 2/41 34.5 % 1.54 [ 0.24, 9.73 ]
Total (95% CI) 660 682 100.0 % 0.82 [ 0.28, 2.42 ]
Total events: 7 (LABA stopped), 9 (LABA continued)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.15, df = 3 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours stopping LABA Favours continuing LABA
(1) Data for the full 52 weeks including ICS dose tapering
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Analysis 1.4. Comparison 1 Stopped LABA vs continued LABA+ICS, Outcome 4 Asthma-related quality of
life.
Review: Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids
Comparison: 1 Stopped LABA vs continued LABA+ICS
Outcome: 4 Asthma-related quality of life
Study or subgroup LABA stopped LABA continued
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Berger 2010 (1) 136 0.27 (0.89) 151 -0.06 (0.9) 79.9 % 0.37 [ 0.13, 0.60 ]
Reddel 2010 (2) 35 1.61 (1.54) 37 1.18 (1.03) 20.1 % 0.33 [ -0.14, 0.79 ]
Total (95% CI) 171 188 100.0 % 0.36 [ 0.15, 0.57 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 3.37 (P = 0.00074)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours stopping LABA Favours continuing LABA
(1) Data for Berger 2010 were measured on the Juniper AQLQ (higher is better) and have been incorporated with permission from Brozek et al (provided to them by
the study sponsor)
(2) Marks Quality of Life Questionnaire - lower values better. Visit 4 (week 12) data before ICS were titrated
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Analysis 1.5. Comparison 1 Stopped LABA vs continued LABA+ICS, Outcome 5 Exacerbation: hospital
admission or emergency department visit.
Review: Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids
Comparison: 1 Stopped LABA vs continued LABA+ICS
Outcome: 5 Exacerbation: hospital admission or emergency department visit
Study or subgroup LABA stopped
Continued
LABA+ICS Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Berger 2010 0/145 0/154 Not estimable
Godard 2008 0/154 0/154 Not estimable
GSK SAS40037 0/161 0/161 Not estimable
Koenig 2008 (1) 0/159 0/172 Not estimable
Reddel 2010 0/41 0/41 Not estimable
0.01 0.1 1 10 100
Favours Stopping LABA Favours LABA + ICS
(1) The absence of hospital admissions for asthma was confirmed with the study sponsors by Brozek et al
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Analysis 1.6. Comparison 1 Stopped LABA vs continued LABA+ICS, Outcome 6 Adverse events (all cause).
Review: Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids
Comparison: 1 Stopped LABA vs continued LABA+ICS
Outcome: 6 Adverse events (all cause)
Study or subgroup LABA stopped LABA continued Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Berger 2010 76/144 90/152 24.0 % 0.77 [ 0.49, 1.22 ]
Godard 2008 42/154 48/154 21.1 % 0.83 [ 0.51, 1.35 ]
GSK SAS40037 84/161 77/161 26.4 % 1.19 [ 0.77, 1.84 ]
Koenig 2008 76/159 100/172 26.8 % 0.66 [ 0.43, 1.02 ]
Reddel 2010 (1) 37/41 39/41 1.7 % 0.47 [ 0.08, 2.75 ]
Total (95% CI) 659 680 100.0 % 0.83 [ 0.66, 1.05 ]
Total events: 315 (LABA stopped), 354 (LABA continued)
Heterogeneity: Tau2 = 0.00; Chi2 = 4.18, df = 4 (P = 0.38); I2 =4%
Test for overall effect: Z = 1.53 (P = 0.13)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours stopping LABA Favours continued LABA
(1) Data for the full 52 weeks including ICS dose tapering
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Analysis 1.7. Comparison 1 Stopped LABA vs continued LABA+ICS, Outcome 7 Withdrawals (all).
Review: Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids
Comparison: 1 Stopped LABA vs continued LABA+ICS
Outcome: 7 Withdrawals (all)
Study or subgroup LABA stopped LABA continued Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Berger 2010 28/145 22/154 20.1 % 1.44 [ 0.78, 2.65 ]
Godard 2008 30/159 18/159 18.9 % 1.82 [ 0.97, 3.42 ]
GSK SAS40037 54/161 38/161 30.3 % 1.63 [ 1.00, 2.66 ]
Koenig 2008 59/159 29/172 27.8 % 2.91 [ 1.74, 4.86 ]
Reddel 2010 6/41 2/41 2.9 % 3.34 [ 0.63, 17.65 ]
Total (95% CI) 665 687 100.0 % 1.95 [ 1.47, 2.58 ]
Total events: 177 (LABA stopped), 109 (LABA continued)
Heterogeneity: Tau2 = 0.01; Chi2 = 4.25, df = 4 (P = 0.37); I2 =6%
Test for overall effect: Z = 4.62 (P < 0.00001)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours stopping LABA Favours continuing LABA
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Analysis 2.1. Comparison 2 Subgroup analysis: type of LABA, Outcome 1 Exacerbation: requiring systemic
corticosteroids.
Review: Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids
Comparison: 2 Subgroup analysis: type of LABA
Outcome: 1 Exacerbation: requiring systemic corticosteroids
Study or subgroup LABA stopped
Continued
LABA+ICS Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Formoterol
Berger 2010 (1) 2/144 1/152 9.5 % 2.13 [ 0.19, 23.71 ]
Subtotal (95% CI) 144 152 9.5 % 2.13 [ 0.19, 23.71 ]
Total events: 2 (LABA stopped), 1 (Continued LABA+ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
2 Salmeterol
Godard 2008 16/154 9/154 76.3 % 1.87 [ 0.80, 4.37 ]
GSK SAS40037 1/161 1/161 7.1 % 1.00 [ 0.06, 16.13 ]
Koenig 2008 1/159 1/172 7.1 % 1.08 [ 0.07, 17.45 ]
Subtotal (95% CI) 474 487 90.5 % 1.70 [ 0.78, 3.72 ]
Total events: 18 (LABA stopped), 11 (Continued LABA+ICS)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.29, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
Total (95% CI) 618 639 100.0 % 1.74 [ 0.83, 3.65 ]
Total events: 20 (LABA stopped), 12 (Continued LABA+ICS)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.32, df = 3 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.86), I2 =0.0%
0.01 0.1 1 10 100
Favours Stopping LABA Favours LABA + ICS
(1) Data for Koenig 2008 and SAS40037 provided to Brozek et al from the study sponsor and reproduced with permission
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Analysis 2.2. Comparison 2 Subgroup analysis: type of LABA, Outcome 2 Asthma control: ACQ.
Review: Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids
Comparison: 2 Subgroup analysis: type of LABA
Outcome: 2 Asthma control: ACQ
Study or subgroup LABA stopped LABA continued
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Formoterol
Berger 2010 (1) 139 0.38 (0.811) 151 0.06 (0.632) 40.9 % 0.32 [ 0.15, 0.49 ]
Subtotal (95% CI) 139 151 40.9 % 0.32 [ 0.15, 0.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.73 (P = 0.00019)
2 Salmeterol
Godard 2008 141 0.8 (0.6) 142 0.6 (0.7) 50.2 % 0.20 [ 0.05, 0.35 ]
Reddel 2010 (2) 35 1.13 (0.86) 37 1.01 (0.69) 8.9 % 0.12 [ -0.24, 0.48 ]
Subtotal (95% CI) 176 179 59.1 % 0.19 [ 0.05, 0.33 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.63 (P = 0.0085)
Total (95% CI) 315 330 100.0 % 0.24 [ 0.13, 0.35 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.56, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 4.41 (P = 0.000011)
Test for subgroup differences: Chi2 = 1.40, df = 1 (P = 0.24), I2 =28%
-1 -0.5 0 0.5 1
Favours stopping LABA Favours continuing LABA
(1) Data for Berger 2010 and Reddel 2010 have been incorporated with permission from Brozek et al (provided to them by the study sponsor)
(2) Visit 4 (week 12) data before ICS were titrated
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Analysis 2.3. Comparison 2 Subgroup analysis: type of LABA, Outcome 3 Serious adverse events.
Review: Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids
Comparison: 2 Subgroup analysis: type of LABA
Outcome: 3 Serious adverse events
Study or subgroup LABA stopped
Continued
LABA+ICS Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Formoterol
Berger 2010 1/145 3/154 22.7 % 0.35 [ 0.04, 3.40 ]
Subtotal (95% CI) 145 154 22.7 % 0.35 [ 0.04, 3.40 ]
Total events: 1 (LABA stopped), 3 (Continued LABA+ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.37)
2 Salmeterol
Godard 2008 1/154 3/154 22.7 % 0.33 [ 0.03, 3.20 ]
GSK SAS40037 2/161 1/161 20.2 % 2.01 [ 0.18, 22.42 ]
Koenig 2008 0/159 0/172 Not estimable
Reddel 2010 (1) 3/41 2/41 34.5 % 1.54 [ 0.24, 9.73 ]
Subtotal (95% CI) 515 528 77.3 % 1.05 [ 0.31, 3.60 ]
Total events: 6 (LABA stopped), 6 (Continued LABA+ICS)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.45, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
Total (95% CI) 660 682 100.0 % 0.82 [ 0.28, 2.42 ]
Total events: 7 (LABA stopped), 9 (Continued LABA+ICS)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.15, df = 3 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Chi2 = 0.69, df = 1 (P = 0.40), I2 =0.0%
0.01 0.1 1 10 100
Favours Stopping LABA Favours LABA + ICS
(1) Data for the full 52 weeks including ICS dose tapering
A D D I T I O N A L T A B L E S
Table 1. All included studies - summary characteristics
Study ID Other ID
(s)
Country
(centres)
Total N Study design Duration Age, years LABA ICS
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Table 1. All included studies - summary characteristics (Continued)
Berger 2010 SD-039-
0726
D5896C00726
NCT00652392
USA (116) 752 R, DB, PC 12 weeks 16+ Formoterol
9 mcg bd
Budesonide
320mcg qd (in-
tervention)
160 mcg bd
(control)
Godard
2008
SAM40088
SFCF4026
France (124) 476 R, DB 24 weeks* 18+ Salmeterol
50 mcg bd
Fluticasone
propionate
250 mcg bd
GSK
SAS40037
SAS40037 USA (87) 824 R, DB, PC 16 weeks 15+ Salmeterol
50 mcg bd
Fluticasone
propionate
100 mcg bd
Koenig
2008
SAS40036 USA (85) 647 R, DB 16 weeks 15+ Salmeterol
50 mcg bd
Fluticasone
propionate
100 mcg bd
Reddel 2010 SAM40031
AC-
TRN12605000465651
Australia (3) 82 R, DB 12 weeks 18+ Salmeterol
50 mcg bd
Fluticasone
propionate
500 mcg bd
Slankard
2011
None USA 69 R, DB 16 weeks 18+ Salmeterol
50 mcg bd
Unclear
Participants were allowed to continue use of their normal rescue inhaler.
*Primary outcome peak flow reported at 12 weeks.
N: number randomly assigned; LABA: long-acting beta2-agonists; ICS: inhaled corticosteroids; R: randomly assigned; DB: double-
blind; PC: placebo-controlled; qd: once daily; bd: twice daily.
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL Monthly
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
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MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search strategy to identify trial reports from the CAGR
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Adrenergic beta-Agonists
#6 beta* NEAR agonist*
#7 LABA*:ti,ab
#8 *formoterol
#9 Foradil
#10 Oxis
#11 salmeterol
#12 vilanterol
#13 Serevent
#14 Seretide or Advair or Viani or Symbicort or Inuvair or Dulera or Adoair or Breo or Relvar
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#15 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14
#16 withdraw*:ti,ab
#17 down-titrat*:ti,ab
#18 discontinu*:ti,ab
#19 stop*:ti,ab
#20 cease*:ti,ab
#21 cessat*:ti,ab
#22 (step-down or “step down”):ti,ab
#23 (reduc* or decreas*) NEAR (dose*):ti,ab
#24 #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23
#25 #4 and #15 and #24
[Note: in search line #1 MISC1 denotes the field in which the reference has been coded for condition, in this case, asthma]
C O N T R I B U T I O N S O F A U T H O R S
Shaleen Ahmad (SA) and Kayleigh Kew (KK) sifted the search and extracted data independently. KK entered data into the analyses,
and all review authors had input on grading evidence quality. SA wrote up the results, with comments and edits from KK and Rebecca
Normansell (RN). All review authors contributed to the discussion and approved the final version of this document.
D E C L A R A T I O N S O F I N T E R E S T
Shaleen Ahmad: none known.
Kayleigh Kew: none known.
Rebecca Normansell: none known.
S O U R C E S O F S U P P O R T
Internal sources
• The authors declare that no internal sources of funding were received for this systematic review, UK.
• Kayleigh Kew, UK.
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External sources
• National Institute for Health Research, UK.
Evidence to guide care in adults and children with asthma, 13/89/14
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We were not able to carry out subgroup analyses for dose of inhaled corticosteroids because all studies reporting primary outcomes
used doses classified as ’low’ in GINA 2014. In addition, we were unable to carry out subgroup analyses for inhaler type because no
studies gave LABA and ICS in separate inhalers. No studies were rated high for risk of bias for blinding, and no unpublished data were
included in the analyses, so there was no need to carry out the planned sensitivity analyses.
We had planned to supplement the main systematic review of effectiveness and safety with a brief economic analysis, but we found no
relevant studies.
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